Seattle And Unum Make Cancer Pact | Chemical & Engineering News
Volume 93 Issue 24 | p. 17 | Concentrates
Issue Date: June 15, 2015

Seattle And Unum Make Cancer Pact

Department: Business
Keywords: pharmaceuticals, biotech, cancer immunotherapy, cellular therapy

Seattle Genetics will pay Unum Therapeutics $25 million to develop antibody-coupled T-cell receptor (ACTR) therapies for cancer. Unum combines engineered T cells with antibodies that can help them home in on cancer cells. Under the pact, which also calls for Seattle Genetics to make a $5 million equity investment in Unum, the partners will develop two ACTRs that use antibodies from Seattle Genetics.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment